Warning: Declaration of subscribe2_widget::addPluginSubMenu() should be compatible with mijnpress_plugin_framework::addPluginSubMenu($title, $function, $file, $capability = 10, $where = 'plugins.ph...') in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18

Warning: Declaration of subscribe2_widget::addPluginContent($links, $file) should be compatible with mijnpress_plugin_framework::addPluginContent($filename, $links, $file, $config_url = NULL) in /data/32/2/10/97/2499423/user/2737425/htdocs/wordpress1/wp-content/plugins/subscribe2-widget/subscribe2-widget.php on line 18
Dyadic International to ring the Nasdaq closing bell on June 17 | SEBIO

Dyadic International to ring the Nasdaq closing bell on June 17

Posted by on Jun 12, 2019

JUPITER, FL. – Dyadic International Inc (NASDAQ:DYAI) said Tuesday that it will spotlight the company’s C1 gene expression technology when founder and CEO Mark Emalfarb and members of the management team ring the Nasdaq closing bell on June 17.

The ceremony will be broadcast live on June 17 starting at 3:45 pm ET from the Nasdaq MarketSite Studio in Times Square, New York City.

READ: Dyadic’s red-hot C1 gene expression technology gets biologic vaccines, drugs to market swiftly at lower cost

Investors will be able to view the live Nasdaq closing bell ringing ceremony at https://livestream.com/nasdaq/live or http://Facebook.com/Nasdaq. The bell ringing portion of the ceremony will also be broadcast on CNBC, Bloomberg TV and Fox Business News, according to the company.

“We are excited to be ringing the Nasdaq Closing Bell to celebrate our recent listing on the Nasdaq Capital Market,” said Emalfarb. “Our recent Nasdaq listing has increased our visibility with investors and the public at large. This added visibility is expected to help us create long-term shareholder value and accelerate the adoption and use of our C1 platform technology to help make healthcare more accessible and affordable to patients.”

Dyadic stock was approved for listing on the tech-laden Nasdaq on April 17.

Founded in 1979, the Jupiter, Florida, biotechnology platform company, has sold a variety of industrial enzymes for more than two decades to the biofuel, animal nutrition, pulp and paper, food, and textile industries.

Three years ago, Dyadic sold its industrial technology business to DuPont’s industrial biosciences business for $75 million in cash.

Dyadic leverages its proprietary C1 technology — an industrially proven fungal gene expression technology for producing large amounts of low-cost biologic products — to help bring biologic vaccines, enzymes, proteins, biosimilars, and drugs to market faster and at a lower cost.


Leave a Reply